Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib De-escalation in BRAF V600 Mutant Low-Grade Gliomas
NCT07110246Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Nov 2025
- Primary completion
- Mar 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in glioma, sponsored by University of California, San Francisco. Started Nov 2025; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07110246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110246.